Johnson & Johnson Says Talvey,Tecvayli Shows Deep,Durable Responses In Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease

Published on 15/06/2025 at 12:52

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Johnson & Johnson

Earnings, inflation data confront resilient US stocks rally	13/07	RE
S&P 500 ends down as tariffs sour sentiment	12/07	RE
FDA May Fast Track Drug Reviews for Lower US Prices	11/07	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	11/07	MT
HSBC Adjusts Johnson & Johnson's Price Target to $180 From $184, Keeps Buy Rating	11/07	MT
Wall St Week Ahead-Earnings, inflation data confront resilient US stocks rally	11/07	RE
Morgan Stanley Adjusts PT on Johnson & Johnson to $171 From $169, Maintains Equalweight Rating	10/07	MT
Jabil Inc. : Investing to stay ahead	10/07
Major deals involving U.S. drugmakers and biotechs over the past decade	09/07	RE
Transgene SA Announces Board Changes	09/07	CI
Johnson & Johnson's Q2 Earnings Call Likely to Focus on Guidance, Tariff Impact, BofA Says	09/07	MT
Company earnings: key dates for next week	09/07
Trump says pharmaceutical tariffs could reach 200%	09/07	RE
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	08/07	MT
Volatility as a Strategy	08/07
J&J: seeks FDA approval for Caplyta for schizophrenia	08/07
Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia	08/07	CI
Johnson & Johnson Submits Supplemental NDA for Schizophrenia Treatment Caplyta	08/07	MT
Nanobiotix: NBTXR3 device reclassified as a drug	08/07
Nanobiotix Reports Regulatory Harmonization, New Composition of Matter Patent Filed for JNJ-1900	08/07	MT
Johnson & Johnson Unit Submits EMA Application to Extend Indication of Akeega for Prostate Cancer	03/07	MT
J&J Unit Seeks Indication Extension for Cancer Drug Combo in EU	03/07	MT
US FDA approves Regeneron's blood cancer therapy	02/07	RE

JOHNSON & JOHNSON

Stock

JNJ

US4781601046

Market Closed - Nyse Other stock markets 01:30:02 18/07/2025 am IST
162.98 ^USD	-1.09%

More quotes

Chart

Duration

Period

JNJ: Dynamic Chart

Income Statement and Estimates

More financial data

Analysis / Opinion

J&J Expects Tariffs to Cost Company $400 Million

Johnson & Johnson: A Dose of Resilience Amid Trade Tensions

April 15, 2025 at 07:24 pm IST

More Strategies

Headlines

Ashish Kacholia and Dolly Khanna: India's Star Investors Send Portfolio Signals

Employment figures offer some respite for the Bank of England

July 17, 2025 at 07:55 pm IST

Results preview: Legrand accelerates

July 17, 2025 at 03:21 pm IST

Crypto companies face the fatal trap of Bitcoin - Crypto roundup

July 17, 2025 at 02:54 pm IST

When volatility boosts US banks

July 17, 2025 at 02:12 pm IST

Shorting the dollar: the most popular trade amongst fund managers

July 17, 2025 at 12:50 pm IST

The Week's Biggest Mergers Unpacked

July 16, 2025 at 07:42 pm IST

Diageo reshuffles its management team: Nik Jhangiani temporarily replaces Debra Crew

July 16, 2025 at 06:59 pm IST

How did Indonesia go from 32% to 19% customs tariffs?

July 16, 2025 at 06:53 pm IST

Rare earths: Apple joins the industrial front supported by the Pentagon

July 16, 2025 at 03:46 pm IST

All our articles